Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Conjugates for cancer/infectious disease treatment covered by U.S. patent

Aug. 30, 1996

LGD-1069 to enter pivotal U.S. trials

Aug. 30, 1996

AG-2034 granted approval for U.S. phase I initiation

Aug. 30, 1996

Phase III trial on Onconase combination initiated

Aug. 30, 1996

Novel antitumor compounds claimed by Kyorin/Sagami

Aug. 23, 1996

Lisofylline undergoes phase III in cancer patients

Aug. 23, 1996

Ethyol extended labeling approved

Aug. 23, 1996

Accelerated drug development program for Oxi-104

Aug. 23, 1996

Antineoplastic agents from Japan Energy

Aug. 23, 1996

VIMRxyn to undergo phase I in glioma patients

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...